1 not yet recruiting, 1 recruiting. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Lingli Dong: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis Xeligekimab injection - Nr-axial Spondyloarthritis, Non-Radiographical Axial Spondyloarthritis | Phase 2 / Phase 3 | Not yet recruiting | Lingli Dong | 40 | 2026-01-31 | 2026-01-14 |
| Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells PRG-1801 （CAR-T against BCMA） - Lupus Nephritis, ANCA Associated Vasculitis | Not applicable | Recruiting | Lingli Dong | 24 | 2024-02-05 | 2024-02-26 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Lupus Nephritis (1) · Non-Radiographic Axial Spondyloarthritis (1)
China (2)